UFP Technologies reported a strong Q1 2023, with a 37.2% increase in sales and a near doubling of EPS. The MedTech business was a key driver, particularly robotic surgery, and gross margins improved substantially due to easing cost pressures and improved efficiency.
Net sales increased by 37.2% compared to Q1 2022.
Net income nearly doubled compared to the same period last year.
MedTech business grew by 59.5%, with robotic surgery segment growing by 112%.
Gross margins increased by 530 basis points to 29.4%.
UFP Technologies anticipates continued synergies from recent investments and a strong pipeline of growth opportunities, positioning the company for future growth.
Analyze how earnings announcements historically affect stock price performance